p-Tau 217 Antibody Specificity for Early Alzheimer’s Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) are ineffective in preventing its progression due to late intervention, and existing anti-tau protein antibodies fail to specifically target pathogenic tau protein, such as phosphorylated tau protein at position 217, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of an antibody or antigen-binding fragment that specifically binds to p-tau 217, comprising specific CDR sequences, allowing for early detection and potential therapeutic intervention in AD and other tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current anti-tau protein antibodies are used, then they can bind to tau protein, but they fail to specifically target pathogenic phosphorylated tau protein at position 217, resulting in suboptimal therapeutic outcomes
Solution Approach 1:
The antibody is designed with specific complementarity determining regions (CDRs) that target the unique phosphorylated epitope at position 217 of tau protein. The VH CDR1 sequence (SEQ ID NO: 3), VH CDR2 sequence (SEQ ID NO: 4), VH CDR3 sequence (SEQ ID NO: 5), VL CDR1 sequence (SEQ ID NO: 6), VL CDR2 sequence (SEQ ID NO: 7), and VL CDR3 sequence (SEQ ID NO: 8) are specifically configured to recognize the phosphorylated serine residue at position 217, providing local specificity to the pathogenic modification rather than binding to all tau protein variants equally.
Solution Approach 2:
The invention changes the binding parameters of the antibody by specifically targeting the phosphorylated form of tau protein at position 217. The antibody's CDR regions are engineered to recognize the phosphoepitope configuration, which alters the binding affinity and specificity compared to non-phosphorylated tau or other phosphorylation sites. This parameter change enables selective binding to the pathogenic form of tau protein associated with Alzheimer's disease progression.
2Loss of time
If clinical treatment is initiated when patients show early clinical symptoms, then treatment can be started, but pathological changes in the body have already appeared, resulting in poor treatment effects
Solution Approach 1:
The antibody enables preliminary detection of pathogenic p-tau 217 before clinical symptoms manifest or when they are just beginning to appear. By specifically targeting the phosphorylated tau protein at position 217, which is an early pathological marker in Alzheimer's disease, the antibody allows for early diagnosis and intervention. This preliminary action enables treatment to be initiated at the preclinical or very early clinical stage, before extensive neuronal damage and neurofibrillary tangle formation occur, thereby improving treatment efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody provides a means for early detection and potential treatment of AD by targeting pathogenic tau protein, potentially delaying or preventing neurodegeneration, and can be used in diagnostic methods and therapeutic interventions.
Implementation Method 1
an antibody or antigen-binding fragment thereof capable of specifically binding to p-tau 217 (tau protein with phosphorylated amino acid at position 217)
Data Source
AI summary
The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.